Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management
More opportunities for shingles protection with recombinant vaccine
+Practice
In print
VACCINES
More opportunities for shingles protection with recombinant vaccine
Wednesday 23 November 2022, 12:30 AM

[Data from Strezova et al (Open Forum Infect Dis 2022;9(10):ofac485)]
This article reviews recent changes to the herpes zoster vaccine used in New Zealand, including recommendations for who should get vaccinated and when
Key points, Herpes zoster is a painful and potentially severe condition.
The risk of post-herpetic neuralgia increases with age.
Two doses of Shingrix are hig, Pract Green w Pale Yellow
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
References
- Bhavsar A, Lonnet G, Wang C, et al. Increased risk of herpes zoster in adults ≥50 years old diagnosed with COVID-19 in the United States. Open Forum Infect Dis 2022;9(5):ofac118.
- Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. NEJM 2016;375(11):1019–32.
- Izurieta HS, Wu X, Forshee R, et al. Recombinant zoster vaccine (Shingrix): Real-world effectiveness in the first 2 years post-licensure. Clin Infect Dis 2021;73(6):941–48.
- Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. NEJM 2015;372(22):2087–96.
- Oostvogels L, Heineman TC, Johnson RW, et al. Medical conditions at enrolment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials. Hum Vacc Immunother 2019;15(12):2865–72.
- Racine E, Gilca V, Amini R, et al. A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18-49-year-old patients. Vaccine 2020;38(40):6205–14.
Figure data from: Strezova A, Diez-Domingo J, Al Shawafi K, et al. Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: Interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination. Open Forum Infect Dis 2022;9(10):ofac485.